Last reviewed · How we verify
Jiangsu Hengrui Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Butorphanol and Propofol | Butorphanol and Propofol | marketed | ||||
| Fentanyl and Propofol | Fentanyl and Propofol | marketed | Opioid agonist + sedative-hypnotic combination | Mu opioid receptor (fentanyl); GABA-A receptor (propofol) | Anesthesiology |
Therapeutic area mix
- Anesthesiology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Jiangsu Hengrui Pharmaceutical Co., Ltd.:
- Jiangsu Hengrui Pharmaceutical Co., Ltd. pipeline updates — RSS
- Jiangsu Hengrui Pharmaceutical Co., Ltd. pipeline updates — Atom
- Jiangsu Hengrui Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Jiangsu Hengrui Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-hengrui-pharmaceutical-co-ltd. Accessed 2026-05-17.